January 11, 2026 — A continued access initiative for Tumor Treating Fields (TTFields) therapy in combination with gemcitabine and nab-paclitaxel has been temporarily paused. This program focuses on patients with locally advanced pancreatic cancer who face limited treatment options. The program, sponsored by NovoCure GmbH, is currently marked as temporarily unavailable.
This news affects clinical professionals, regulatory teams, and the broader medical device and oncology communities closely following advances in pancreatic cancer care.
- What changed?
- Who is affected?
- Regulatory context and implications
- Frequently Asked Questions
- Conclusion
- Disclaimer
What changed?
The access program for TTFields therapy combined with chemotherapy agents gemcitabine and nab-paclitaxel is currently not available. NovoCure GmbH, the program sponsor, has not provided details about the timeframe for resumption.
This program is tied to the PANOVA-3CA study, which developed to support treatment in locally advanced pancreatic adenocarcinoma patients, particularly those unable to undergo surgery. The sudden pause raises questions about accessibility for patients relying on this innovative therapy pending further updates from the manufacturer.
Who is affected?
Patients suffering from locally advanced pancreatic adenocarcinoma are directly impacted. These patients often face limited options due to the challenging nature of this cancer stage. TTFields therapy, used as an adjunct to chemotherapy agents gemcitabine and nab-paclitaxel, aimed to slow tumor progression and extend life expectancy.
Medical professionals and oncology teams utilizing or investigating integrated device-drug therapies in clinical settings must anticipate potential delays in applying this approach. Clinical trial coordinators may need to advise affected patients accordingly while awaiting updates.
Regulatory context and implications
TTFields therapy is a non-invasive treatment method designed to disrupt cancer cell division using electric fields. NovoCure, as the program’s sponsor, operates under stringent regulations applicable to both the medical device and drug components involved. Any program pause typically reflects adherence to evolving regulatory, safety, or logistical requirements.
Professionals monitoring this program should note the implications for ongoing studies or expanded access scenarios. Ensuring compliance with applicable frameworks, including MDR Annex XIV in Europe or FDA regulatory pathways in the United States, remains critical for all stakeholders involved.
For organizations managing clinical trials, this pause serves as a reminder of the complexities surrounding combined treatments and the importance of planning for potential registration or regulatory review pauses during trial phases.
Frequently Asked Questions
- Why has the program been paused?
The exact reason for the pause has not been disclosed. It may reflect regulatory, safety, or logistical considerations. Stakeholders are advised to await updates from NovoCure GmbH. - How soon will the program resume?
No specific resumption timeline has been shared. Updates from the sponsor will clarify further actions or reopening dates. - Who can I contact for more information?
Healthcare providers participating in the program can reach out to NovoCure GmbH or reference ClinicalTrials.gov for updates and additional contact details.
Conclusion
The temporary unavailability of the continued access program for TTFields therapy highlights ongoing challenges in providing innovative treatments to patients with locally advanced pancreatic cancer. Regulatory and clinical teams should monitor updates from NovoCure and consider adjusting strategies to manage patient needs during this time.
Disclaimer
This article is for informational purposes only and does not constitute legal or clinical advice. Always refer to official guidance or medical recommendations.
Announcement line
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07319910?term=medical+device